Hepion Pharmaceuticals, Inc.
HEPA
$0.07
-$0.02-18.82%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.67M | 6.12M | 7.50M | 7.48M | 7.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.28M | 15.44M | 19.35M | 25.36M | 31.57M |
| Operating Income | -8.28M | -15.44M | -19.35M | -25.36M | -31.57M |
| Income Before Tax | -13.56M | -16.44M | -16.16M | -26.08M | -31.74M |
| Income Tax Expenses | 0.00 | 0.00 | -2.97M | -3.38M | -3.38M |
| Earnings from Continuing Operations | -13.56 | -16.44 | -13.19 | -22.70 | -28.37 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.56M | -16.44M | -13.19M | -22.70M | -28.37M |
| EBIT | -8.28M | -15.44M | -19.35M | -25.36M | -31.57M |
| EBITDA | -8.27M | -15.44M | -19.32M | -25.32M | -31.51M |
| EPS Basic | -49.56 | -83.31 | -109.29 | -223.67 | -324.59 |
| Normalized Basic EPS | -35.06 | -80.54 | -128.02 | -167.48 | -231.38 |
| EPS Diluted | -49.56 | -83.31 | -109.29 | -223.67 | -324.59 |
| Normalized Diluted EPS | -35.06 | -80.54 | -128.02 | -167.48 | -231.38 |
| Average Basic Shares Outstanding | 14.44M | 3.23M | 491.20K | 440.00K | 382.40K |
| Average Diluted Shares Outstanding | 14.44M | 3.23M | 491.20K | 440.00K | 382.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |